Introduction
Cancer is a serious disease, and drug therapy is currently the most efficient strategy for curing cancer. However, the low complete remission rate, and recurrence and metastasis have limited the advancement of this method [1, 11] , and it is necessary to develop new anticancer drugs for therapy. In cell signaling pathways, key protein kinases, particularly protein tyrosine kinases (PTKs), play an important role in cancer cell proliferation. The PTK family is classified into receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases according to structural features [8] . Signal transduction is activated by receptor autophosphorylation on tyrosine residues when PTK receptors bind their specific ligands [3] . The receptors with PTK activity are important in the control of cancer cell proliferation. Plateletderived growth factor receptor (PDGFR), epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), and kinase insert domain receptor (KDR) belong to the RTK family. Two forms of PDGFR, α and β, are cell surface tyrosine kinase receptors for platelet-derived growth factor and are closely related to vascular proliferation and cancer. Overexpression or excessive activation of PDGFRβ can stimulate tumor angiogenesis and growth. Therefore, blocking or inhibiting the overexpression of tyrosine kinase activity is a current trend in tumor therapy [2, 4] . EGFR is a type of glycoprotein receptor on the cell membrane and the product of the HER-1 proto-oncogenes [6, 13] . Two strategies have been proposed to cure cancer; developing a monoclonal antibody against the extracellular domain of EGFR [9, 20] , and identifying small molecule inhibitors that specifically inhibit the active domain of the kinase to disrupt autophosphorylation and signal transduction [22] .
Protein tyrosine phosphorylation is important in cell signaling and is involved in many physiological activities, such as tissue differentiation and growth, sugar and fat metabolism, and the immune response [15, 17] . Protein tyrosine phosphatase 1B (PTP1B), also known as PTPN1, is the first purified mammalian PTP and is considered as a reference prototype for following PTP studies [10] . Protein tyrosine phosphorylation is precisely regulated by the balance of PTKs and PTPs [14] .
The preparation of active recombinant protein tyrosine kinases is useful for a target protein and model molecule during drug screening programs to identify anticancer therapeutics. PTK expression in recombinant P. pastoris is difficult and most likely occurs because the PTKs phosphorylate intracellular proteins, which disturbs cellular homeostasis and results in toxicity to the host cells [18] . In this study, the co-expression of PTKs with PTPs in P. pastoris was used to facilitate the expression of active PTKs by neutralizing their apparent toxicity to cells.
Materials and Methods

Bacterial Strains, Plasmids, and Culture Conditions
The bacterial strains and plasmids used in this study are listed in Table 1 . Escherichia coli was grown at 37°C in Luria-Bertani medium (LB; Oxoid, Basingstoke, UK). P. pastoris was grown at 30°C in four different media [21] : YPD medium (1% yeast extract, 2% glucose, and 2% peptone), synthetic yeast nitrogen base (YNB) medium, MGY medium (1.34% YNB, 1% glycerol, and 0.4 mg/ml biotin), and minimal methanol (MM) medium (1.34% YNB, 0.4 mg/ml biotin, and 0.5% methanol). Antibiotics or other reagents purchased from Sigma (St. Louis, MO, USA) were selectively added (750 µg/ml hygromycin, 50 µg/ml ampicillin, 50 µg/ml kanamycin, or 300 µg/ml G418).
Plasmid and Strain Construction
General recombinant DNA techniques were performed according to standard protocols [7] . The plasmids were constructed and transformed into P. pastoris using electroporation [19] . All DNA sequencing and oligo syntheses (Table S1 ) were performed by Invitrogen Co. (Shanghai, China).
Construction of PTP1B expression strains. PTP1B and PTP1B-SKL (PTP1B-peroxisomal targeting signal 1) sequences were amplified from the plasmid pCMV6-XL5 using primers P1 and P2-1 or P2-2, respectively (Supplemental Table S1 ). The products were cloned into the BamHI/EcoRI sites of pPIC3.5K to construct plasmids pPIC3.5-PTP1B and pPIC3.5-PTP1B-SKL. Primers A1 and A2 were used to amplify the resultant plasmids and produce AOX1-PTP1B-AOX (TT) and AOX1-PTP1B-SKL-AOX (TT) ( Table S1 ). The two derivatives were ligated with the StuI/SalI-digested pAG32S vector to produce plasmids pAG32S-PTP1B and pAG32S-PTP1B-SKL, which were then confirmed by PCR with primers A1/A2 (Table S1 ) and DNA sequencing. The positive plasmids were linearized by Bpu1102I (EspI) digestion and electroporated into P. pastoris GS115 to produce strains 2Y and 1Y. Using the templates pAG32S-PTP1B and pAG32S-PTP1B-SKL, PCR was performed to generate the -SphI-PTP1B-pAG32S-KpnI-and -SphI-PTP1B-SKL-pAG32S-KpnI-fragments with primer pair AGup/ AGdown, respectively (Table S1 ). To introduce the BFP, the -KpnI-BFP-SphI-fragment was amplified from plasmid pDRM054 using primer pair Bup/Bdown and inserted into SphI/KpnI-digested -SphI-PTP1B-pAG32S-KpnI-and -SphI-PTP1B-SKL-pAG32S-KpnIto produce pAG32S-BFP-PTP1B and pAG32S-BFP-PTP1B-SKL. The positive plasmids were linearized by Bpu1102I(EspI) digestion and electroporated into P. pastoris GS115 to produce strains 4Y and 3Y.
Construction of PDGFRβ and EGFR-2 expression strains. To construct the PTK expression strains, the gene encoding PDGFRβ was amplified from pcDNA3.1-PDGFRβ using primers T71/T72, whereas the gene encoding EGFR-2 was amplified from pcDNApBluescriptIISK (+) with primers X51/X52. The two fragments were linked with SpeI/NotI-digested pPIC3.5K-His-GFP-SpeI-PDGFRβ-SKL-NotI or pPIC3.5K-His-GFP-SpeI-EGFR-2-SKL-NotI plasmids to generate pPIC3.5K-Kozak-His 10 -linker-GFPLinker-Thrombin site-PDGFRβ-SKL (pPIC3.5-GFP-PDGFRβ-SKL) or pPic3.5-Kozak-His 10 -linker-GFP-Linker-Thrombin site-EGFR-2-SKL (pPIC3.5-GFP-EGFR2-SKL), respectively. These plasmids were confirmed by PCR with primers T71/T72 or X51/X52 (Table S1 ) and DNA sequencing. The positive plasmids pPIC3.5-GFP-PDGFRβ-SKL and pPIC3.5-GFP-EGFR2-SKL were linearized by either SalI or PmiI digestion and electroporated into P. pastoris GS115 and 1Y, 2Y, 3Y, 4Y to produce strains PD, 1PPD~4PPD, E, and 1EP~4EP, respectively.
Preparation of EGFR-2 and PDGFRβ Proteins
Strains 1EP, 2EP, 3EP, 4EP, and E were cultured in shaking flasks. Flow cytometry (FACScalibur; Becton Dickinson, Franklin Lakes, NJ, USA) was used to determine the GFP expression level in P. pastoris. The cell extract was prepared as described previously [21] . The protein concentration was measured according to the method of Bradford (Tiangen Ltd., Shanghai, China). Western blotting was performed to determine the EGFR-2 expression level [21] . His-tag affinity and ion-exchange chromatographies were performed on the AKTA Explorer 100 purification system (Pharmacia Bioscience) to purify the EGFR protein. The EGFR kinase activity and inhibition rate, using poly(Glu 4 -Tyr) as the substrate, were assayed by ELISA using a tyrosine kinase assay kit (Millipore). The preparation of PDGFRβ was done in the same way as for EGFR-2.
Results
Construction of Phosphatase PTP1B Expression Vectors
In this study, the gene encoding phosphatase PTP1B with/without BFP or SKL was cloned into the expression vector pAG32 and successfully produced four vectors, pAG32S-PTP1B, pAG32S-PTP1B-SKL, pAG32S-BFP-PTP1B, and pAG32S-BFP-PTP1B-SKL. The sizes of the PCR amplification products using primers A1/A2 were 2,642, 2,651, 3,368, and 3,377 bp, respectively. The plasmids were linearized Vector expressing the c-Src gene SIMM a and electroporated into P. pastoris GS115 under the control of an inducible AOX1 promoter resulting in P. pastoris strains 2Y, 1Y, 4Y, and 3Y. The strains were grown on Hisdeficient plates with a hygromycin resistance gene as a marker. The positive strains were determined by PCR (Supplemental Figs. S1A and S1B) and sequencing. After 24 h methanol induction, the fluorescence in strain 3Y was not dispersed throughout the cells but showed a punctate distribution (Figs. S1C and S1D). The reason for this may be that the BFP was targeted into the P. pastoris peroxisomes because of the carboxyl-terminal signal peptide SKL [12] . For strain 4Y without the signal peptide SKL, the BFP-PTP1B protein was expressed and distributed in the cytoplasm, and the fluorescence was dispersed throughout the cells (Figs. S1E and S1F).
Construction of EGFR-2 and PDGFRβ Expression Vectors
Each of the EGFR-2 and PDGFRβ genes was cloned and expressed in vector pPIC3.5K fused with a His-tag and GFP at its N-terminus. The fusion plasmids were transformed into four P. pastoris strains with PTP1B (1Y-4Y) and the control GS115 strain to obtain 10 strains: E, 1EP~4EP, PD and 1PPD-4PPD (Table 1) : all of which were under the control of an inducible AOX1 promoter. To avoid the potential negative effect to host cells caused by PTK phosphorylation, SKL was added to the C-terminus of EGFR-2 and PDGFR to produce vectors pPIC3.5-GFP-EGFR2-SKL and pPIC3.5-GFP-PDGFRβ-SKL. The correct P. pastoris transformants were screened on His-deficient plates, followed by YPD-G418 plates after transforming the control strain GS115 and strains 1Y-4Y with PTP1B.
To further verify the strains, PCR amplification of strains E, 1EP, 2EP, 3EP, and 4EP was performed with primers A1/X52 or X51/X52 and a product of 1,675 bp was obtained. Using templates 1PPD, 2PPD, 3PPD, and 4PPD and primers T71/T72 or P1/P2, products of 1,572 and 1,313 bp were obtained by PCR amplification, respectively.
Co-Expression of BFP-PTP1B-and GFP-Fused RTKs in P. pastoris P. pastoris strains containing pPIC3.5-GFP-PDGFRβ-SKL and pPIC3.5-GFP-EGFR2-SKL expressed GFP-SKL, whereas those with pAG32S-BFP-PTP1B or pAG32S-BFP-PTP1B-SKL expressed BFP or BFP-SKL. The BFP-SKL or GFP-SKL proteins specifically targeted the peroxisome of P. pastoris [12] . In the 10 recombinant P. pastoris strains (Table 1) , the subcellular location of GFP-or BFP-fused PTP1B, EGFR-2, and PDGFRβ were investigated by fluorescence microscopy (Fig. 1) . Co-expression of BFP with GFP in P. pastoris strains 3EP, 4EP, 3PPD, and 4PPD was detected with fluorescence microscopy, and blue or green fluorescence was observed (Figs. 1C, 1D , 1G, and 1H) indicating that PTP1B can be coexpressed with EGFR-2 and PDGFRβ in P. pastoris.
In strains 4EP and 4PPD (Figs. 1D and 1H ), the blue fluorescence was nearly widespread in the entire cells, whereas the green fluorescence exhibited a typical punctuate pattern. Without the carboxyl-terminal SKL, the BFP-PTP1B was expressed in the cytoplasm. However, GFP-PDGFRβ-SKL and GFP-EGFR2-SKL were expressed and located in the peroxisome because of the signal peptide SKL. By contrast, for strains 3EP and 3PPD, a typical punctate blue and green fluorescence was observed and overlapped, which suggests that the fusion proteins BFP-PTP1B-SKL, GFP-PDGFRβ-SKL, and GFP-EGFR2-SKL were all sorted into the peroxisome under the control of the SKL signal (Figs. 1C and 1G ). For control strains E containing pPIC3.5-GFP-PDGFRβ-SKL (Fig. 1I) and PD containing pPIC3.5-GFP-EGFR2-SKL (Fig. 1J) , or PTP1B without BFP (Figs. 1A, 1B, 1E , and 1F), only green fluorescence was observed. Expression, Purification, and Activity Analysis of EGFR-2 and PDGFRβ Proteins Five strains, 1EP, 2EP, 3EP, 4EP, and E, were cultured and induced with methanol in shaking flasks and sampled at 24 h intervals.
After 48 h induction, the wet cell weight (WCW) was measured. The WCW of P. pastoris GS115Gal, a control strain that expressed β-galactosidase intracellularly, was 4.1 g/l. However, strain E grew significantly slower than the control strain. The WCW of strain E was 1.2 g/l ( Table 2) , which was only 29.3% of the control. When there was co-expression with PTP1B, strains 1EP-4EP grew more rapidly. In particular, for strain 3EP, the WCW reached 1.9 g/l, which was almost 58.3% higher than strain E.
Green fluorescence intensity was detected by flow cytometry to determine the expression of EGFR-2 in each strain according to the fused GFP expression and to select high-yield strains. Under methanol induction, GFP was expressed in strains E and 1EP-4EP, and a maximum was achieved after 24 h in strain 3EP ( Table 2 ). The same induction and detection of GFP in strains PD and 1PPD-4PPD were also performed (data not shown).
EGFR-2 and PDGFRβ were purified using His-tag affinity and ion-exchange chromatographies. By western blotting, the EGFR-2 and PDGFRβ fusion proteins in the cell lysate were 92 and 89 kDa, respectively (Fig. 2) .
The tyrosine kinase EGFR-2 is a potential target for anticancer drug screening. The tyrosine kinase activity of EGFR-2 was measured using an ELISA (Table 2 , Fig. 3A) . High kinase activity EGFR-2 was obtained from a His-tag affinity column with a 250 mM imidazole elution. Moreover, the highest kinase activity was achieved by strain 3EP (Table 2) , which was consistent with the green fluorescence intensity of this strain.
The molecular model for screening EGFR-2 inhibitors was investigated. Tyrosine kinase substrate phosphorylation is a complex, double-substrate, including poly(Glu4-Tyr) and ATP, enzymatic process. The concentration of one substrate is first determined, and the other substrate is then changed to demonstrate its relationship with the phosphorylation reaction. When the ATP concentration was fixed in a range of 1-10 µM, substrate phosphorylation increased significantly with an increase in the ATP concentration (data not shown). The optimal concentration of poly(Glu 4 -phospho-Tyr) and ATP was 10 ng/well and 5 mM, respectively. With an increase of EGFR-2 and PDGFRβ, substrate phosphorylation increased rapidly and reached a plateau when EGFR-2 was 48 ng/well (Fig. 3A) and PDGFRβ was 39 ng/well (Fig. 3B) . When co-expressed with PTP1B (strains 1EP-4EP and 1PPD-4PPD), the tyrosine kinase activity was higher than when it was expressed alone (strains E and PD) (Fig. 3) .
Discussion
Tyrosine kinases are the most important therapeutic target for the treatment of cancer because of their critical role in angiogenesis. However, the preparation of PTKs Cell pellets grown in MGY medium were washed with water and then resuspended in MM medium to an OD 600 of 1.0 for methanol induction for 48 h in shake flasks.
The WCW was then measured.
b The Geo-Mean GFP fluorescence intensities were calculated with 10 4 cells per analysis. (A) Cell pellets grown in MM medium for 24 h were disrupted and centrifuged, and the supernatant was analyzed by western blot assay using a GFP antibody. Lane 1, strain 1EP; Lane 2, strain 2EP; Lane 3, strain 3EP; Lane 4, strain 4EP expressing the GFP-EGFR-2 fusion protein in P. pastoris. (B) Cell pellets grown in MM medium for 24 h were disrupted and centrifuged, and the supernatant was purified by Ni 2+ affinity chromatography. The affinity elutions were evaluated by western blot analysis using a GFP antibody. Lane 1, strain 1PPD; Lane 2, strain 2PPD; Lane 3, strain 3PPD; Lane 4, strain 4PPD expressing the GFP-PDGFRβ fusion protein in P. pastoris.
using recombinant P. pastoris is difficult primarily because PTKs phosphorylate intracellular proteins and result in serious growth inhibition and toxicity to host cells [18] . In this study, we co-expressed PTKs and PTPs in P. pastoris to overcome the potential negative effect caused by overexpression of PTKs. P. pastoris can use methanol as the sole carbon and energy source because of the expression of alcohol oxidase (AOX1 and AOX2) induced by methanol. Exogenous gene expression is strictly controlled by the promoter P AOX [5] . Methanol is catabolized in the peroxisome, which facilitates the separation of toxic metabolic products from the cell components [16] . To decrease the toxicity of PTK expression, the tyrosine kinases EGFR-2 and PDGFRβ were expressed and targeted to the peroxisome of P. pastoris by peroxisomal targeting signal 1 (SKL). Phosphatase PTP1B with/without SKL were co-expressed with EGFR-2 and PDGFRβ. The activity of the PTKs co-expressed with PTP1B was compared with that without PTP1B in P. pastoris after growth in medium containing methanol.
The results indicated that the co-expression of tyrosine phosphatase PTP1B and a tyrosine kinase in P. pastoris could partially recover the growth of P. pastoris and increase the expression level of tyrosine kinase. Cell growth of strain E was significantly inhibited by EGFR-2 expression, and its WCW was only 29.3% of the control (Table 2) . However, when co-expressed with PTP1B, strains 1EP~4EP grew more rapidly. In particular, strain 3EP was almost 58.3% higher than strain E. Moreover, for PTK expression, the kinase activity in strains 1EP-4EP was also higher than strain E. The highest kinase activity was achieved by strain 3EP (Table 2) , which was 81.5% higher than strain E. When co-expressed with PTP1B (strain 1EP-4EP, 1PPD-4PPD), the tyrosine kinase activity was higher than when expressed alone (strain E, PD) in the molecular model test (Fig. 3) .
The growth and kinase activity results demonstrate that co-expression of tyrosine phosphatase PTP1B and tyrosine kinases in P. pastoris can partly overcome the negative effects associated with overexpression of tyrosine kinases. The establishment of a co-expression system provides a valuable tool for the production of protein tyrosine kinases, which interferes with the level of protein phosphorylation in host cells.
